论文部分内容阅读
目的:探讨益生菌对肠易激综合征患者肠道微环境及免疫功能的影响,为临床相关研究提供参考。方法:选择2013年6月-2015年6月在我院接受治疗的肠易激综合征患者79例作为研究对象,根据治疗方案不同分为研究组(47例)和对照组(42例)。研究组患者采用双歧三联活菌联合美沙拉嗪治疗,对照组患者给予美沙拉嗪治疗。观察并比较两组患者治疗前后肠道内肠杆菌、双歧杆菌、乳酸杆菌、粪肠球菌及类杆菌的变化情况,以及血清CD4~+,CD8~+及CD4~+/CD8~+水平,并评价两组的临床疗效。结果:治疗前,两组患者肠道菌群数量比较,差异无统计学意义(P>0.05);治疗后,两组患者肠道内大肠杆菌及粪肠球菌数量均减少,且研究组少于对照组,差异具有统计学意义(P<0.05);治疗后,两组患者肠道内乳酸杆菌、双歧杆菌和类杆菌数量均增加,且研究组高于对照组,差异具有统计学意义(P<0.05)。治疗前,两组患者免疫功能指标比较,差异无统计学意义(P>0.05);治疗后,两组患者CD4~+T细胞以及CD4~+/CD8~+均显著高于治疗前,而CD8~+T细胞显著降低,差异具有统计学意义(P<0.05);治疗后,研究组患者CD4~+T细胞及CD4~+/CD8~+均高于对照组,而CD8+T细胞低于对照组,差异具有统计学意义(P<0.05)。研究组患者的临床疗效(91.67%)高于对照组(76.67%),但两组比较,差异无统计学意义(P>0.05)。结论:益生菌制剂治疗不仅能够调节肠易激综合征患者肠道内的菌群平衡,而且能够改善患者的免疫功能,值得临床推广应用。
Objective: To investigate the effect of probiotics on gut microenvironment and immune function in patients with irritable bowel syndrome and to provide references for clinical research. Methods: A total of 79 patients with irritable bowel syndrome (IBS) treated in our hospital from June 2013 to June 2015 were selected as the study group and divided into the study group (n = 47) and the control group (n = 42) according to the different treatment regimens. Patients in the study group were treated with live bifidobacterium combined with mesalazine and those in the control group with mesalazine. The changes of Enterobacteriaceae, Bifidobacterium, Lactobacillus, Enterococcus faecalis and Bacteroides in the intestine before and after treatment were observed and compared. The levels of CD4 ~ +, CD8 ~ + and CD4 ~ + / CD8 ~ Evaluation of the clinical efficacy of both groups. Results: Before treatment, there was no significant difference in intestinal microflora between the two groups (P> 0.05). After treatment, the numbers of Escherichia coli and Enterococcus faecalis in both groups decreased, and the study group was less than the control group (P <0.05). After treatment, the numbers of Lactobacillus, Bifidobacterium and Bacteroides in both groups increased after treatment, and the difference between the two groups was statistically significant (P < 0.05). Before treatment, there was no significant difference in immune function between the two groups (P> 0.05). After treatment, CD4 ~ + T cells and CD4 ~ + / CD8 ~ + in both groups were significantly higher than those before treatment, while CD8 (P <0.05). After treatment, CD4 ~ + T cells and CD4 ~ + / CD8 ~ + in study group were significantly higher than those in control group, while CD8 + T cells were lower than Control group, the difference was statistically significant (P <0.05). The clinical efficacy of the study group was 91.67% higher than that of the control group (76.67%), but there was no significant difference between the two groups (P> 0.05). Conclusion: The treatment of probiotics not only can regulate intestinal microflora balance in patients with irritable bowel syndrome, but also improve the immune function of patients, which is worthy of clinical application.